

Oriol Busquets

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3052746/publications.pdf>

Version: 2024-02-01

33
papers

784
citations

566801

15
h-index

525886

27
g-index

54
all docs

54
docs citations

54
times ranked

1392
citing authors

#	ARTICLE	IF	CITATIONS
1	Memantine for the Treatment of Dementia: A Review on its Current and Future Applications. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 1223-1240.	1.2	150
2	Long-term exposition to a high fat diet favors the appearance of I ² -amyloid depositions in the brain of C57BL/6J mice. A potential model of sporadic Alzheimer's disease. <i>Mechanisms of Ageing and Development</i> , 2017, 162, 38-45.	2.2	79
3	ADAM10 in Alzheimer's disease: Pharmacological modulation by natural compounds and its role as a peripheral marker. <i>Biomedicine and Pharmacotherapy</i> , 2019, 113, 108661.	2.5	52
4	Epigallocatechin-3-Gallate (EGCG) Improves Cognitive Deficits Aggravated by an Obesogenic Diet Through Modulation of Unfolded Protein Response in APP ^{swe} /PS1 ^{dE9} Mice. <i>Molecular Neurobiology</i> , 2020, 57, 1814-1827.	1.9	51
5	The Implication of the Brain Insulin Receptor in Late Onset Alzheimer's Disease Dementia. <i>Pharmaceuticals</i> , 2018, 11, 11.	1.7	45
6	The Involvement of Peripheral and Brain Insulin Resistance in Late Onset Alzheimer's Disease Dementia. <i>Frontiers in Aging Neuroscience</i> , 2019, 11, 236.	1.7	40
7	Dexibuprofen prevents neurodegeneration and cognitive decline in APP ^{swe} /PS1 ^{dE9} through multiple signaling pathways. <i>Redox Biology</i> , 2017, 13, 345-352.	3.9	36
8	Benzodiazepines and Related Drugs as a Risk Factor in Alzheimer's Disease Dementia. <i>Frontiers in Aging Neuroscience</i> , 2019, 11, 344.	1.7	35
9	Experimental Models for Aging and their Potential for Novel Drug Discovery. <i>Current Neuropharmacology</i> , 2018, 16, 1466-1483.	1.4	35
10	JNK1 inhibition by Licochalcone A leads to neuronal protection against excitotoxic insults derived of kainic acid. <i>Neuropharmacology</i> , 2018, 131, 440-452.	2.0	28
11	Peripheral and Central Effects of Memantine in a Mixed Preclinical Mice Model of Obesity and Familial Alzheimer's Disease. <i>Molecular Neurobiology</i> , 2018, 55, 7327-7339.	1.9	24
12	Early Preclinical Changes in Hippocampal CREB-Binding Protein Expression in a Mouse Model of Familial Alzheimer's Disease. <i>Molecular Neurobiology</i> , 2018, 55, 4885-4895.	1.9	21
13	JNK Isoforms Are Involved in the Control of Adult Hippocampal Neurogenesis in Mice, Both in Physiological Conditions and in an Experimental Model of Temporal Lobe Epilepsy. <i>Molecular Neurobiology</i> , 2019, 56, 5856-5865.	1.9	20
14	Role of JNK isoforms in the kainic acid experimental model of epilepsy and neurodegeneration. <i>Frontiers in Bioscience - Landmark</i> , 2017, 22, 795-814.	3.0	19
15	A metabolic perspective of late onset Alzheimer's disease. <i>Pharmacological Research</i> , 2019, 145, 104255.	3.1	19
16	Role of c-Jun N-Terminal Kinases (JNKs) in Epilepsy and Metabolic Cognitive Impairment. <i>International Journal of Molecular Sciences</i> , 2020, 21, 255.	1.8	18
17	Anti-inflammatory role of Leptin in glial cells through p38 MAPK pathway inhibition. <i>Pharmacological Reports</i> , 2017, 69, 409-418.	1.5	15
18	Pharmacological Strategies to Improve Dendritic Spines in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2021, 82, S91-S107.	1.2	13

#	ARTICLE	IF	CITATIONS
19	A Chronological Review of Potential Disease-Modifying Therapeutic Strategies for Alzheimer's Disease. <i>Current Pharmaceutical Design</i> , 2020, 26, 1286-1299.	0.9	12
20	The Ethyl Acetate Extract of Leaves of <i>Ugni molinae</i> Turcz. Improves Neuropathological Hallmarks of Alzheimer's Disease in Female APP ^{swe} /PS1 ^{dE9} Mice Fed with a High Fat Diet. <i>Journal of Alzheimer's Disease</i> , 2018, 66, 1175-1191.	1.2	10
21	c-Jun N-terminal Kinase 1 ablation protects against metabolic-induced hippocampal cognitive impairments. <i>Journal of Molecular Medicine</i> , 2019, 97, 1723-1733.	1.7	10
22	Involvement of JNK1 in Neuronal Polarization During Brain Development. <i>Cells</i> , 2020, 9, 1897.	1.8	8
23	c-Jun N-Terminal Kinases in Alzheimer's Disease: A Possible Target for the Modulation of the Earliest Alterations. <i>Journal of Alzheimer's Disease</i> , 2021, 82, S127-S139.	1.2	7
24	Dexibuprofen ameliorates peripheral and central risk factors associated with Alzheimer's disease in metabolically stressed APP ^{swe} /PS1 ^{dE9} mice. <i>Cell and Bioscience</i> , 2021, 11, 141.	2.1	7
25	Dysregulation of Insulin-Linked Metabolic Pathways in Alzheimer's Disease: Co-Factor Role of Apolipoprotein E ε4. <i>Journal of Alzheimer's Disease Reports</i> , 2020, 4, 479-493.	1.2	7
26	Role of brain c-Jun N-terminal kinase 2 in the control of the insulin receptor and its relationship with cognitive performance in a high-fat diet pre-clinical model. <i>Journal of Neurochemistry</i> , 2019, 149, 255-268.	2.1	6
27	Triple GLP-1/GIP/glucagon receptor agonists, a potential novel treatment strategy in Alzheimer's disease. <i>Expert Opinion on Investigational Drugs</i> , 2019, 28, 93-97.	1.9	5
28	The preclinical discovery and development of opicapone for the treatment of Parkinson's disease. <i>Expert Opinion on Drug Discovery</i> , 2020, 15, 993-1003.	2.5	5
29	Potential preventive disease-modifying pharmacological strategies to delay late onset Alzheimer's disease. <i>Neural Regeneration Research</i> , 2019, 14, 1721.	1.6	2
30	JNK1 and JNK3: divergent functions in hippocampal metabolic-cognitive function. <i>Molecular Medicine</i> , 2022, 28, 48.	1.9	2
31	JNK isoforms control mammal adult hippocampal neurogenesis. <i>Mexican Journal of Medical Research ICSA</i> , 2020, 8, 5-12.	0.2	1
32	GSPE pre-treatment protects against long-term cafeteria diet-induced mitochondrial and inflammatory affectations in the hippocampus of rats. <i>Nutritional Neuroscience</i> , 2022, 25, 2627-2637.	1.5	1
33	EPIGALLOGATECHIN-3-GALLATE IMPROVES COGNITIVE DECLINE AND METABOLIC ALTERATIONS IN APP/PS1 FAMILIAL MODEL OF ALZHEIMER'S DISEASE FED WITH HIGH FAT DIET. <i>Proceedings for Annual Meeting of the Japanese Pharmacological Society</i> , 2018, WCP2018, PO1-1-32.	0.0	0